136.48
price down icon1.02%   -1.40
 
loading
DaVita Inc stock is currently priced at $136.48, with a 24-hour trading volume of 592.57K. It has seen a -1.02% decreased in the last 24 hours and a +5.16% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $137.5 pivot point. If it approaches the $135.4 support level, significant changes may occur.
Previous Close:
$137.88
Open:
$137.56
24h Volume:
592.57K
Market Cap:
$11.97B
Revenue:
$12.34B
Net Income/Loss:
$815.64M
P/E Ratio:
27.13
EPS:
5.03
Net Cash Flow:
$920.34M
1W Performance:
-1.06%
1M Performance:
+5.16%
6M Performance:
+44.07%
1Y Performance:
+38.53%
1D Range:
Value
$136.39
$138.56
52W Range:
Value
$71.51
$145.04

DaVita Inc Stock (DVA) Company Profile

Name
Name
DaVita Inc
Name
Phone
303-405-2100
Name
Address
2000 16th Street, Denver, CO
Name
Employee
74,500
Name
Twitter
@DaVita
Name
Next Earnings Date
2024-06-06
Name
Latest SEC Filings
Name
DVA's Discussions on Twitter

DaVita Inc Stock (DVA) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-07-23 Upgrade UBS Neutral → Buy
Nov-01-22 Downgrade Deutsche Bank Buy → Hold
Oct-31-22 Downgrade UBS Buy → Neutral
Aug-19-22 Resumed UBS Buy
Jun-21-22 Reiterated BofA Securities Underperform
Sep-10-21 Initiated Cowen Market Perform
Aug-12-21 Downgrade Barclays Overweight → Equal Weight
Mar-26-21 Downgrade BofA Securities Neutral → Underperform
Jan-05-21 Downgrade BofA Securities Buy → Neutral
Jan-24-20 Upgrade Goldman Neutral → Buy
Nov-07-19 Downgrade Raymond James Outperform → Mkt Perform
Oct-25-19 Downgrade Wolfe Research Outperform → Peer Perform
Sep-11-19 Downgrade William Blair Outperform → Mkt Perform
Jul-26-19 Downgrade Robert W. Baird Outperform → Neutral
Jan-08-19 Upgrade UBS Sell → Neutral
Jan-03-19 Initiated Deutsche Bank Buy
Dec-14-18 Initiated Barclays Overweight
Nov-28-18 Upgrade Raymond James Mkt Perform → Outperform
Nov-16-18 Initiated UBS Sell
Nov-08-18 Downgrade Raymond James Strong Buy → Mkt Perform
Sep-13-18 Upgrade JP Morgan Underweight → Neutral
Jan-04-18 Upgrade BofA/Merrill Neutral → Buy
Dec-12-17 Upgrade Robert W. Baird Neutral → Outperform
Dec-11-17 Upgrade Citigroup Neutral → Buy
Dec-07-17 Upgrade Raymond James Outperform → Strong Buy
Nov-08-17 Reiterated RBC Capital Mkts Sector Perform
Oct-09-17 Downgrade JP Morgan Neutral → Underweight
Jun-26-17 Downgrade Jefferies Buy → Hold
Dec-13-16 Downgrade Robert W. Baird Outperform → Neutral
View All

DaVita Inc Stock (DVA) Financials Data

DaVita Inc (DVA) Revenue 2024

DVA reported a revenue (TTM) of $12.34 billion for the quarter ending March 31, 2024, a +5.77% rise year-over-year.
loading

DaVita Inc (DVA) Net Income 2024

DVA net income (TTM) was $815.64 million for the quarter ending March 31, 2024, a +58.74% increase year-over-year.
loading

DaVita Inc (DVA) Cash Flow 2024

DVA recorded a free cash flow (TTM) of $920.34 million for the quarter ending March 31, 2024, a -14.54% decrease year-over-year.
loading

DaVita Inc (DVA) Earnings per Share 2024

DVA earnings per share (TTM) was $8.80 for the quarter ending March 31, 2024, a +62.36% growth year-over-year.
loading

DaVita Inc Stock (DVA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
DESOER BARBARA J
Director
May 10 '24
Sale
138.81
5,030
698,214
10,954
STAFFIERI MICHAEL DAVID
Chief Operating Officer, DKC
Mar 13 '24
Option Exercise
52.41
50,000
2,620,500
102,748
Rodriguez Javier
Chief Executive Officer
Mar 06 '24
Option Exercise
67.80
750,000
50,850,000
1,244,480
ACKERMAN JOEL
CFO and Treasuer
Mar 06 '24
Option Exercise
52.41
55,000
2,882,550
195,360
STAFFIERI MICHAEL DAVID
Chief Operating Officer, DKC
Mar 06 '24
Option Exercise
52.41
50,000
2,620,500
87,687
Rodriguez Javier
Chief Executive Officer
Feb 28 '24
Option Exercise
67.80
50,000
3,390,000
531,300
Rodriguez Javier
Chief Executive Officer
Feb 27 '24
Sale
126.87
7,397
938,467
481,300
Rodriguez Javier
Chief Executive Officer
Feb 26 '24
Option Exercise
67.80
450,000
30,510,000
889,002
Rodriguez Javier
Chief Executive Officer
Feb 26 '24
Sale
126.11
67,603
8,525,130
488,697
STAFFIERI MICHAEL DAVID
Chief Operating Officer, DKC
Feb 21 '24
Option Exercise
52.41
100,000
5,241,000
137,687
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.
medical_care_facilities UHS
$178.98
price down icon 1.79%
medical_care_facilities THC
$127.93
price down icon 3.79%
medical_care_facilities FMS
$22.39
price down icon 0.09%
medical_care_facilities EHC
$85.44
price down icon 1.89%
medical_care_facilities CHE
$568.37
price up icon 0.07%
Cap:     |  Volume (24h):